$IONS
IONIS PHARMACEUTICALS INC Stock $ions

$ions Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000110465913060361 Filed on August 06, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$38.09M	$47.34M
YoY Change	-19.54%	90.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.400M	$3.200M
YoY Change	6.25%	10.34%
% of Gross Profit
Research & Development	$42.63M	$40.44M
YoY Change	5.43%	12.29%
% of Gross Profit
Depreciation & Amortization	$2.400M
YoY Change
% of Gross Profit
Operating Expenses	$46.02M	$43.64M
YoY Change	5.44%	12.24%
Operating Profit	-$7.928M	$3.696M
YoY Change	-314.5%	-126.29%
Interest Expense	$4.808M	$5.219M
YoY Change	-7.88%	51.85%
% of Operating Profit		141.21%
Other Income/Expense, Net
YoY Change
Pretax Income	-$11.31M	-$1.207M
YoY Change	836.79%	-93.25%
Income Tax	-$1.200M	$0.00
% Of Pretax Income
Net Earnings	-$10.10M	-$1.200M
YoY Change	741.67%	-93.3%
Net Earnings / Revenue	-26.51%	-2.53%
Basic Earnings Per Share
Diluted Earnings Per Share	-$81.98K	-$0.01
COMMON SHARES
Basic Shares Outstanding	108.5M shares	100.2M shares
Diluted Shares Outstanding	108.5M shares	100.2M shares

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$590.8M	$336.0M
YoY Change	75.82%	-14.98%
Cash & Equivalents	$296.5M	$85.65M
Short-Term Investments	$294.2M	$250.4M
Other Short-Term Assets	$5.786M	$5.700M
YoY Change	1.51%	-25.0%
Inventory	$8.300M	$7.100M
Prepaid Expenses
Receivables	$2.000M	$1.600M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$669.1M	$350.4M
YoY Change	90.93%	-14.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$88.31M	$94.00M
YoY Change	-6.05%	6.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		-$5.563M
YoY Change
Other Assets	$5.600M	$2.500M
YoY Change	124.0%	-24.24%
Total Long-Term Assets	$119.6M	$122.0M
YoY Change	-1.96%	2.59%
TOTAL ASSETS
Total Short-Term Assets	$669.1M	$350.4M
Total Long-Term Assets	$119.6M	$122.0M
Total Assets	$788.7M	$472.4M
YoY Change	66.95%	-10.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.461M	$6.200M
YoY Change	52.6%	100.0%
Accrued Expenses	$16.51M	$20.60M
YoY Change	-19.83%	34.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.900M	$5.300M
YoY Change	-7.55%	8.16%
Total Short-Term Liabilities	$87.00M	$55.06M
YoY Change	57.99%	-40.15%
LONG-TERM LIABILITIES
Long-Term Debt	$225.4M	$225.7M
YoY Change	-0.13%	12.12%
Other Long-Term Liabilities	$75.20M	$37.30M
YoY Change	101.61%	54.77%
Total Long-Term Liabilities	$300.6M	$263.0M
YoY Change	14.3%	16.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$87.00M	$55.06M
Total Long-Term Liabilities	$300.6M	$263.0M
Total Liabilities	$387.6M	$318.1M
YoY Change	21.85%	0.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$918.8M
YoY Change
Common Stock	$1.293B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$401.1M	$154.3M
YoY Change
Total Liabilities & Shareholders Equity	$788.7M	$472.4M
YoY Change	66.95%	-10.8%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$10.10M	-$1.200M
YoY Change	741.67%	-93.3%
Depreciation, Depletion And Amortization	$2.400M
YoY Change
Cash From Operating Activities	$22.80M	-$2.600M
YoY Change	-976.92%	-90.08%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	-$800.0K
YoY Change	-50.0%	-76.47%
Acquisitions
YoY Change
Other Investing Activities	-$31.50M	$24.80M
YoY Change	-227.02%	-11.43%
Cash From Investing Activities	-$31.80M	$24.10M
YoY Change	-231.95%	-2.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$173.3M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	197.9M	7.800M
YoY Change	2437.18%	2500.0%
NET CHANGE
Cash From Operating Activities	22.80M	-2.600M
Cash From Investing Activities	-31.80M	24.10M
Cash From Financing Activities	197.9M	7.800M
Net Change In Cash	188.9M	29.30M
YoY Change	544.71%	-2541.67%
FREE CASH FLOW
Cash From Operating Activities	$22.80M	-$2.600M
Capital Expenditures	-$400.0K	-$800.0K
Free Cash Flow	$23.20M	-$1.800M
YoY Change	-1388.89%	-92.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	isis	Fair Value Assets Transfer Between Level1 And Level2 Amount FairValueAssetsTransferBetweenLevel1AndLevel2Amount	0	USD
CY2012Q4	isis	Significant Equity Investment SignificantEquityInvestment	33622000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296540000	USD
CY2012Q2	isis	Fair Value Assets Transfer Between Level1 And Level2 Amount FairValueAssetsTransferBetweenLevel1AndLevel2Amount	0	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6121000	USD
	isis	Variable Interest Entity Not Primary Beneficiary Number Of Entities VariableInterestEntityNotPrimaryBeneficiaryNumberOfEntities	5	item
CY2012	isis	Variable Interest Entity Not Primary Beneficiary Number Of Entities VariableInterestEntityNotPrimaryBeneficiaryNumberOfEntities	6	item
CY2013Q2	us-gaap	Variable Interest Entity Nonconsolidated Carrying Amount Assets VariableInterestEntityNonconsolidatedCarryingAmountAssets	63600000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26986000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17784000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	968000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	9202000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	1210000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	15669000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	1738000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-1163000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14506000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12480000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-770000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1738000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	6300000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	10000000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2636000	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2460000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5505000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4727000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of estimates</font></b></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></p> </div>
CY2013Q2	isis	Available For Sale Securities Debt Maturities Within One Year Percentage AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage	0.57	pure
CY2013Q2	isis	Available For Sale Securities Debt Maturities After One Through Two Years Percentage AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage	0.26	pure
CY2013Q2	isis	Available For Sale Securities Debt Maturities After Two Through Three Years Percentage AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeYearsPercentage	0.17	pure
CY2013Q2	isis	Available For Sale Securities Debt Maturities Total Percentage AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage	1.00	pure
CY2013Q2	isis	Available For Sale Securities Debt Maturities Within Two Years Percentage AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage	0.83	pure
CY2013Q2	isis	Number Of Privately Held Companies In Which Entity Has Equity Investment NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment	3	company
CY2013Q2	isis	Number Of Publicly Held Companies In Which Entity Has Equity Investment NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment	3	company
CY2012Q4	us-gaap	Cost Method Investments CostMethodInvestments	625000	USD
CY2012Q4	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	625000	USD
CY2013Q2	us-gaap	Cost Method Investments CostMethodInvestments	625000	USD
CY2013Q2	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	625000	USD
CY2013Q2	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	744000	USD
CY2013Q2	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions	98	security
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	185216000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	9900000	USD
CY2013Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	294212000	USD
CY2013Q2	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	2024000	USD
CY2013Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	8309000	USD
CY2013Q2	isis	Significant Equity Investment SignificantEquityInvestment	62190000	USD
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	5786000	USD
	dei	Entity Registrant Name EntityRegistrantName	ISIS PHARMACEUTICALS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0000874015
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	115307756	shares
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	124482000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	249964000	USD
CY2012Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	522000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	669061000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88312000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8727000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	423438000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91084000	USD
CY2012Q4	isis	Licenses Net LicensesNet	6579000	USD
CY2012Q4	isis	Patents Net PatentsNet	18646000	USD
CY2012Q4	isis	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	5939000	USD
CY2012Q4	us-gaap	Assets Assets	545686000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10239000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7878000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15401000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	4879000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35925000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	74322000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	66656000	USD
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	143990000	USD
CY2012Q4	isis	Capital Lease And Other Long Term Borrowings Non Current CapitalLeaseAndOtherLongTermBorrowingsNonCurrent	7402000	USD
CY2012Q4	isis	Long Term Financing Obligation LongTermFinancingObligation	70550000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	362920000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	102000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1077150000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-906966000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	182766000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	545686000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	788651000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	401081000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9461000	USD
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7031000	USD
CY2013Q2	isis	Licenses Net LicensesNet	5528000	USD
CY2013Q2	isis	Patents Net PatentsNet	20149000	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16514000	USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114291999	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114291999	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101481134	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101481134	shares
CY2012Q2	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	47140000	USD
	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	1618000	USD
CY2012Q2	us-gaap	Revenues Revenues	47340000	USD
	us-gaap	Revenues Revenues	70575000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40435000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79149000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3209000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6185000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	43644000	USD
	us-gaap	Operating Expenses OperatingExpenses	85334000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3696000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14759000	USD
CY2012Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-163000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1139000	USD
CY2012Q2	us-gaap	Investment Income Net InvestmentIncomeNet	477000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	1077000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	5219000	USD
	us-gaap	Interest Expense InterestExpense	10398000	USD
CY2012Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	2000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	19000	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1207000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25200000	USD
	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	2000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1207000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25202000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100213000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100185000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100213000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100185000	shares
CY2013Q2	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-1181000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10126000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11307000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13042000	USD
	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-1244000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11798000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	46020000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7928000	USD
CY2013Q2	us-gaap	Revenues Revenues	38092000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6304000	USD
	us-gaap	Operating Expenses OperatingExpenses	87755000	USD
	us-gaap	Revenues Revenues	81451000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1210000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1738000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23464000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9288000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	116653000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	142681000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	864000	USD
	isis	Payments To Acquire Licenses And Other Assets PaymentsToAcquireLicensesAndOtherAssets	1592000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	23572000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-47148000	USD
	isis	Proceeds From The Sale Of Strategic Investments ProceedsFromTheSaleOfStrategicInvestments	1938000	USD
	us-gaap	Interest Expense InterestExpense	9603000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	4808000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1617000	USD
	isis	Proceeds From Equipment Financing Arrangement ProceedsFromEquipmentFinancingArrangement	9100000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	4833000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5884000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	20168000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	172058000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	207042000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	12164000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-924000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2708000	USD
CY2013Q2	isis	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	5601000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85645000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65477000	USD
	us-gaap	Interest Paid InterestPaid	2275000	USD
	isis	Noncash Capital And Patent Expenditures NoncashCapitalAndPatentExpenditures	679000	USD
CY2012Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-242000	USD
CY2013Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9617869	shares
CY2013Q2	us-gaap	Share Price SharePrice	19.00
CY2013Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	173200000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	USD
CY2013Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9500000	USD
CY2013Q2	us-gaap	Assets Assets	788651000	USD
CY2013Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	8727000	USD
CY2013Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	4853000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	40409000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	86995000	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	75184000	USD
CY2013Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	147099000	USD
CY2013Q2	isis	Capital Lease And Other Long Term Borrowings Non Current CapitalLeaseAndOtherLongTermBorrowingsNonCurrent	7382000	USD
CY2013Q2	isis	Long Term Financing Obligation LongTermFinancingObligation	70910000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	387570000	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	114000	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1292745000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-918764000	USD
CY2013Q2	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	37615000	USD
CY2013Q2	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	477000	USD
	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	79535000	USD
	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	1916000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42631000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3389000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6811000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80944000	USD
CY2013Q2	us-gaap	Investment Income Net InvestmentIncomeNet	589000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	967000	USD
CY2013Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	840000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1898000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108539000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108539000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105225000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105225000	shares
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9202000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15669000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	96926000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	591000	USD
	isis	Payments To Acquire Licenses And Other Assets PaymentsToAcquireLicensesAndOtherAssets	1171000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	36879000	USD
	isis	Proceeds From Equipment Financing Arrangement ProceedsFromEquipmentFinancingArrangement	2513000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	5573000	USD
	us-gaap	Interest Paid InterestPaid	2977000	USD
	isis	Noncash Capital And Patent Expenditures NoncashCapitalAndPatentExpenditures	1055000	USD
	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	46000000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	275000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	288000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	173223000	USD
CY2013Q2	isis	Sale Of Stock Number Of Shares Issued At Over Allotment Option SaleOfStockNumberOfSharesIssuedAtOverAllotmentOption	617869	shares

Files In Submission

Name	View Source	Status
0001104659-13-060361-index-headers.html	Edgar Link	pending
0001104659-13-060361-index.html	Edgar Link	pending
0001104659-13-060361.txt	Edgar Link	pending
0001104659-13-060361-xbrl.zip	Edgar Link	pending
a13-13715_110q.htm	Edgar Link	pending
a13-13715_1ex10d1.htm	Edgar Link	pending
a13-13715_1ex10d2.htm	Edgar Link	pending
a13-13715_1ex31d1.htm	Edgar Link	pending
a13-13715_1ex31d2.htm	Edgar Link	pending
a13-13715_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
isis-20130630.xml	Edgar Link	completed
isis-20130630.xsd	Edgar Link	pending
isis-20130630_cal.xml	Edgar Link	unprocessable
isis-20130630_def.xml	Edgar Link	unprocessable
isis-20130630_lab.xml	Edgar Link	unprocessable
isis-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IONS
IONIS PHARMACEUTICALS INC Stock $ions

2013 Q2 Form 10-Q Financial Statement

#000110465913060361 Filed on August 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IONS IONIS PHARMACEUTICALS INC Stock $ions

2013 Q2 Form 10-Q Financial Statement

#000110465913060361 Filed on August 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IONS
IONIS PHARMACEUTICALS INC Stock $ions